Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

OUP (Osage University Partners)

Investor type University Program
Founders Robert Adelson

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 203
Average round size
info
The average size of a deal this fund participated in
$34M
Portfolio companies 111
Rounds per year 15.62
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.45
Exits 37
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2009 was created OUP (Osage University Partners), which is appeared as VC. The main office of represented VC is situated in the Bala Cynwyd. The fund was located in North America if to be more exact in United States.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Artificial Intelligence. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Receptos, Cardioxyl Pharmaceuticals, Guardant Health.

This organization was formed by Robert Adelson. We also calculated 5 valuable employees in our database.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2017. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The typical startup value when the investment from OUP (Osage University Partners) is 50-100 millions dollars. The fund is constantly included in 7-12 deals per year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this OUP (Osage University Partners) works on 9 percentage points less the average amount of lead investments.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the OUP (Osage University Partners), startups are often financed by OrbiMed, BioAdvance, Sutter Hill Ventures. The meaningful sponsors for the fund in investment in the same round are Sutter Hill Ventures, The Column Group, HBM Healthcare Investments AG. In the next rounds fund is usually obtained by General Catalyst, Lux Capital, OrbiMed.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of OUP (Osage University Partners):
Typical Co-investors
OUP (Osage University Partners) is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after OUP (Osage University Partners):

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Normunity

Biotechnology
Medical
Therapeutics
$65M25 Oct 2022 West Haven, Connecticut, United States

Metalenz

3D Technology
Consumer Electronics
Manufacturing
Semiconductor
Sensor
$30M05 Oct 2022 Boston, Massachusetts, United States

Delfi Diagnostics

Biotechnology
Health Care
Health Diagnostics
$225M18 Jul 2022 Baltimore, Maryland, United States

Nikola Labs Inc.

Consumer Electronics
Electrical Distribution
Industrial Automation
Industrial Manufacturing
Internet of Things
$9M27 Jun 2022 Ohio, United States

MicroTransponder

Health Care
Medical
Medical Device
$73M20 Jun 2022 Dallas, Texas, United States

Brimstone Energy

Chemical
Energy
Natural Resources
$55M24 Mar 2022 Berkeley, California, United States

Antiva Biosciences

Biotechnology
Health Care
Medical
$31M02 Nov 2021 California, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$80M21 Oct 2021 Dallas, Texas, United States

Vanqua Bio

Biotechnology
Health Care
Medical
$85M14 Sep 2021 Chicago, Illinois, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent OUP (Osage University Partners)?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: